1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019) Authors: Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Issue 6 (June 2020) Authors: Tolaney, Sara M; Wardley, Andrew M; Zambelli, Stefania; Hilton, John F; Troso-Sandoval, Tiffany A; Ricci, Francesco; Im, Seock-Ah; Kim, Sung-Bae; Johnston, Stephen RD; Chan, Arlene; Goel, Shom; Catron, Kristen; Chapman, Sonya C; Price, Gregory L; Yang, Zhengyu; Gainford, M Corona; André, Fabrice Journal: Lancet oncology Issue: Volume 21:Issue 6(2020) Page Start: 763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Issue 6 (June 2017) Authors: Earl, Helena M; Hiller, Louise; Howard, Helen C; Dunn, Janet A; Young, Jennie; Bowden, Sarah J; McDermaid, Michelle; Waterhouse, Anna K; Wilson, Gregory; Agrawal, Rajiv; O'Reilly, Susan; Bowman, Angela; Ritchie, Diana M; Goodman, Andrew; Hickish, Tamas; McAdam, Karen; Cameron, David; Dodwell, Dav... Journal: Lancet oncology Issue: Volume 18:Issue 6(2017:Jun.) Page Start: 755 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Issue 10 (October 2020) Authors: Turner, Nicholas C; Kingston, Belinda; Kilburn, Lucy S; Kernaghan, Sarah; Wardley, Andrew M; Macpherson, Iain R; Baird, Richard D; Roylance, Rebecca; Stephens, Peter; Oikonomidou, Olga; Braybrooke, Jeremy P; Tuthill, Mark; Abraham, Jacinta; Winter, Matthew C; Bye, Hannah; Hubank, Michael; Gevensl... Journal: Lancet oncology Issue: Volume 21:Issue 10(2020) Page Start: 1296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Letrozole: advancing hormone therapy in breast cancer. (November 2012) Authors: Lee, Rebecca J; Armstrong, Anne C; Wardley, Andrew M Journal: Women's health Issue: Volume 8:Number 6(2012) Page Start: 611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply. Issue 10223 (15th February 2020) Authors: Earl, Helena M; Hiller, Louise; Plummer, Chris; Miles, David; Wardley, Andrew M; Cameron, David A; Dunn, Janet A Journal: Lancet Issue: Volume 395:Issue 10223(2020) Page Start: 492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗